Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Blinklab Limited ( (AU:BB1) ) has provided an update.
BlinkLab has formed a partnership with the U.S.-based SHANK2 Autism Foundation, a non-profit focused on SHANK2-related neurodevelopmental disorders, to access a genetically defined patient population and validate its digital behavioural biomarkers. By working with this well-characterised cohort, the company aims to strengthen its precision diagnostics, improve AI-driven digital phenotyping, and generate cleaner datasets through collaboration with patient registries and specialist researchers.
The alliance is strategically important for expanding BlinkLab’s platform beyond autism screening into broader rare neurodevelopmental and neurological indications, positioning its technology for use in future clinical trial endpoints and patient stratification tools. Against a backdrop of increasing regulatory focus on biologically defined neurodevelopmental conditions, including recent FDA support for targeted therapies, the partnership may enhance BlinkLab’s appeal as a commercial partner to drug developers working on rare synaptic and neurodevelopmental disorders.
More about Blinklab Limited
BlinkLab Limited is an ASX-listed company developing a digital neurodiagnostic platform that uses smartphone-based neurometric and behavioural assessments. Its technology focuses on digital biomarkers and precision diagnostics for autism and other neurodevelopmental and neurological disorders, with growing interest in applications for rare, genetically defined conditions and potential partnerships with pharmaceutical and biotechnology companies.
Average Trading Volume: 216,302
Technical Sentiment Signal: Buy
Current Market Cap: A$103.9M
See more data about BB1 stock on TipRanks’ Stock Analysis page.